Elevance Health (NYSE:ELV) Given New $457.00 Price Target at Barclays

Elevance Health (NYSE:ELV) had its price objective dropped by stock analysts at Barclays from $480.00 to $457.00 in a report issued on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price target points to a potential upside of 17.23% from the company’s current price.

Other analysts have also issued research reports about the stock. Robert W. Baird upped their target price on shares of Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a research note on Thursday, April 23rd. Citigroup upgraded shares of Elevance Health to a “buy” rating in a research note on Wednesday, April 29th. Bank of America boosted their target price on shares of Elevance Health from $435.00 to $460.00 and gave the company a “buy” rating in a report on Thursday, June 4th. Leerink Partners set a $364.00 price target on Elevance Health in a report on Thursday, April 23rd. Finally, Jefferies Financial Group decreased their price objective on Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. Fifteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $439.57.

Elevance Health Stock Performance

NYSE:ELV opened at $389.85 on Thursday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. Elevance Health has a fifty-two week low of $273.71 and a fifty-two week high of $436.24. The company has a 50 day simple moving average of $399.67 and a two-hundred day simple moving average of $355.07. The company has a market capitalization of $84.66 billion, a PE ratio of 16.58, a P/E/G ratio of 2.42 and a beta of 0.67.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, July 15th. The company reported $7.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.21 by $1.24. The company had revenue of $49.83 billion for the quarter, compared to the consensus estimate of $48.88 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm’s revenue was up .8% compared to the same quarter last year. During the same period in the previous year, the business earned $8.84 EPS. Research analysts anticipate that Elevance Health will post 26.86 earnings per share for the current year.

Insider Activity at Elevance Health

In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total transaction of $60,667.27. Following the transaction, the director directly owned 10,734 shares of the company’s stock, valued at approximately $4,312,599.18. This trade represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.34% of the company’s stock.

Institutional Trading of Elevance Health

Several institutional investors have recently added to or reduced their stakes in the business. WealthCollab LLC boosted its stake in shares of Elevance Health by 42.2% during the first quarter. WealthCollab LLC now owns 91 shares of the company’s stock valued at $27,000 after purchasing an additional 27 shares during the period. Kemnay Advisory Services Inc. bought a new stake in Elevance Health in the 4th quarter worth $31,000. J.Safra Asset Management Corp purchased a new position in shares of Elevance Health in the fourth quarter valued at about $32,000. ORG Partners LLC boosted its holdings in shares of Elevance Health by 120.4% during the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after purchasing an additional 59 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in Elevance Health during the 4th quarter valued at approximately $38,000. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

Key Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Elevance Health beat Q2 expectations on both earnings and revenue, with EPS of $7.45 versus estimates around $6.18-$6.21 and revenue of $49.83 billion topping forecasts. Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
• Positive Sentiment: The company raised its 2026 adjusted EPS guidance to at least $27.00, signaling management is more confident in profit trends and medical cost control for the rest of the year. Elevance raises annual profit forecast on better medical cost management
• Positive Sentiment: Analyst sentiment remained supportive, with Truist lifting its price target to $475 and reiterating a buy rating after the earnings update. Elevance Health (NYSE:ELV) Price Target Raised to $475.00 at Truist Financial
• Neutral Sentiment: Recent earnings-call coverage highlighted growth opportunities in CarelonRx and operating improvements, but also noted that the company is navigating strain from higher costs and softer membership trends. Elevance Health earnings call: growth levers amid strain
• Negative Sentiment: Despite the earnings beat, some reports said the shares slipped on margin pressure and the company is leaving more Medicaid markets, which could weigh on investor sentiment around future growth. Elevance Health (ELV) Beats Q2 And Raises Outlook While Leaving More Medicaid Markets

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.